SCHEMBL6278740

SCHEMBL6278740

Cc1nc([Si](C)(C)C)c2c(c1[Si](C)(C)C)COC2

nearest known ligand 0.33

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9606752 0.63 KDM4E (0.41) KDM4E
SCHEMBL7758239 0.58 KDM4E (0.38) KDM4E
SCHEMBL31041484 0.56 KDM4E (0.33) KDM4E
SCHEMBL13259344 0.56 BRD4 (0.31) KDM4E
SCHEMBL14214190 0.55 KDM4E (0.36) KDM4E
SCHEMBL31707825 0.55 KDM4E (0.36) KDM4E
SCHEMBL4442902 0.54 MB (0.33) KDM4E
SCHEMBL10843176 0.54 MB (0.33) KDM4E
SCHEMBL31041481 0.54 LMNA (0.48) KDM4E
SCHEMBL19056384 0.54 BRD4 (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2005090356-A1 1,3 DIHYDROFURO [3,4-c]PYRIDINES AND THEIR PREPARATION DSM IP ASSETS B.V. (NL) 2005-09-29 WO disclosed
US-20040242885-A1 Manufacture of vitamin b6 DSM IP ASSETS B.V. (NL) 2004-12-02 US disclosed
EP-1430062-A2 MANUFACTURE OF VITAMIN B6 DSM IP Assets B.V. (NL) 2004-06-23 EP disclosed
WO-2003027121-A2 MANUFACTURE OF VITAMIN B6 DSM IP ASSETS B.V. (NL) 2003-04-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040242885-A1 Manufacture of vitamin b6 LIG1, LIG3, LIG4 KDM4E 581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.